After Eli Lilly submits an NDA and FDA completes review (typically 10-12 months), a realistic US commercial availability window is 2027 at the earliest, contingent on trial data and Lilly's filing timeline
"It totally blindsided me - I had a tumour the size of a tangerine which had a cyst attached to it," Kirsty said
Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Companys ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR
Conservative starting doses would be essential: Initial phase : Cagrilintide 0.3 mg + Tirzepatide 2.5 mg weekly Escalation : Increase cagrilintide by 0.3-0.6 mg every 4 weeks Tirzepatide adjustment : Maintain or modestly increase based on tolerance Monitoring : Close observation for cumulative GI effects This remains speculative, as no published trials have examined this specific combination
Our weight loss program in Gun Barrel City, Texas uses GLP-1 medications including Ozempic, Mounjaro, Wegovy, Zepbound, and more to help patients lose weight and reach their goals under the guidance of a licensed provider
